Sentences with phrase «stem cell replacement therapies»
«You can manipulate stem cells and propagate them in a dish, but many recipients of stem cell replacement therapies will be older individuals.
https://www.sciencedaily.com/
He is particularly interested in the mechanisms and molecules that regulate neural stem cell maintenance, cell fate programming and neural stem cell replacement therapies.
«Skeletal muscle created from stem cells: Discovery is major step towards a stem cell replacement therapy for Duchenne Muscular Dystrophy.»
The findings are a major step towards developing a stem cell replacement therapy for muscle diseases including Duchenne Muscular Dystrophy, which affects approximately 1 in 5,000 boys in the U.S. and is the most common fatal childhood genetic disease.
ViaCyte's stem cell replacement therapy for the treatment of type 1 diabetes was highlighted in a June 2012 Popular Science article on artificial organs.
Not exact matches
«For the broad application of stem cell - derived pituitary cells in the future, cell replacement therapy may need to be customized to the specific needs of a given patient population,» Zimmer says.
With these findings, Helmholtz Zentrum München scientists have discovered key molecular functions of stem cell differentiation which could be used for beta cell replacement therapy in diabetes.
Cell therapy, as envisaged by the teams of I - Stem, is primarily based on the identification of experimental protocols that can specifically guide differentiation of pluripotent cells to a cell fate, which presents a interest for the replacement of the defective cell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etCell therapy, as envisaged by the teams of I - Stem, is primarily based on the identification of experimental protocols that can specifically guide differentiation of pluripotent cells to a cell fate, which presents a interest for the replacement of the defective cell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etcell fate, which presents a interest for the replacement of the defective cell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etcell population from the patient (the striatal neurons for Huntington's disease, the cells of the retinal pigment epithelium for retinitis pigmentosa, keratinocytes for genodermatoses, etc.).
«ViaCyte was the first to differentiate human stem cells into glucose - responsive, insulin - producing cells, and now we are running the first and only clinical trials of stem cell - derived islet replacement therapies for type 1 diabetes,» said Paul Laikind, PhD, President and CEO of ViaCyte.
ViaCyte's PEC - EncapTM (also known as VC - 01TM) product candidate is the first pluripotent stem cell - derived islet cell replacement therapy for the treatment of type 1 diabetes in clinical - stage development.
In addition, ViaCyte launched the first clinical trials for stem cell - derived islet replacement therapies for type 1 diabetes.
SAN DIEGO and BETHESDA, MD, March 3, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Eugene Brandon, Director of Strategic Relations and Project Management, at the JDRF TypeOneNation Summit.
SAN DIEGO, April 20, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced four presentations at upcoming healthcare events.
The third and final day of the 2016 Huntington's Disease Therapeutics Conference brings updates on cell replacement therapies including stem cells; and new ways to assess and model the progression of HD to help understand it and run crucial clinical trials.
This information could then be used to prompt embryonic stem cells to differentiate in the culture dish into neurons for potential use in cell - replacement therapy.
Comparisons of genetically matched human pluripotent stem cells reveals that somatic cell nuclear transfer is the ideal means of generating cells for replacement therapy
For the first time, researchers demonstrate long term success of a cell replacement therapy using autologous induced pluripotent stem cell derivatives
Basically what was happening when you use a hematopoietic stem cell to correct an inherited metabolic disease is that through engraftment of that cell you are allowing that cell to become the replacement source for the missing enzyme or other factor - almost like a cellular form of gene therapy or, as I call it, «poor man's gene therapy».
Scientists publishing in the journal Cell Stem Cell have reported the production of functional human oocytes from discarded genetic material, a process which they suggest could one day assist in fertility treatment or mitochondrial replacement therapy.
While many important developments impacted the field, two that garnered significant public, political and scientific attention in 2016 were the proliferation of clinics using unproven stem cell «therapies,» and the steps forward in therapeutic modification of human oocytes (unfertilized eggs) through a process called mitochondrial replacement therapy (MRT).
SAN DIEGO, September 9, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced participation on a panel at the 2016 BioPharm ™ America — 9th Annual International Partnering Conference.
In addition, we use our expertise to facilitate the development of functionally mature beta cells from embryonic stem cells for cell replacement therapies of type 1 diabetes.
SAN DIEGO, March 17, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Paul Laikind, President and CEO, at the third annual Regen Med Investor Day co-hosted by the Alliance for Regenerative Medicine (ARM) and top financial firm Piper Jaffray.
In addition, the funding will be used to support other operations including the continued development of the PEC - Encap ™ product candidate, ViaCyte's stem cell - derived islet replacement therapy that is being developed as a treatment for all diabetes patients who require insulin to control their disease.
Cell replacement therapies require clinically safe stem cells that can be used to generate many (possibly all) types of cells.
The first - in - human STEP ONE * trial is evaluating the safety and efficacy of ViaCyte's PEC - Encap (a.k.a. VC - 01 ™) product candidate, a stem cell - derived, encapsulated cell replacement therapy.
STEP ONE is the first trial in the world investigating a stem cell - derived beta cell replacement therapy for diabetes.
San Diego, January 8, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's Phase 1/2 clinical trial of its VC - 01TM product candidate.
San Diego, California, October 6, 2014 — ViaCyte, Inc., a privately - held regenerative medicine company developing a stem cell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follstem cell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follcell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follStem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follCell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follows:
«We are grateful to CIRM and the citizens of California for their continued support of our potentially transformative stem cell - derived, cell replacement therapies for diabetes,» said Paul Laikind, Ph.D., President and CEO of ViaCyte.
Ultimately, we use all this information to establish innovative culture techniques for generating unlimited neural stem cell sources for the derivation of specific types of clinically relevant neuronal or glial cells, for their use in disease modelling and drug discovery platforms, and towards refining their efficacy for future cell replacement - based therapy.
ViaCyte has two stem cell - based islet cell replacement therapies in clinical development.
SAN DIEGO, March 1, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced presentations at the JDRF TypeOneNation Summit meetings being held in Washington DC and Los Angeles.
The PEC - Encap (also known as VC - 01) product candidate is designed to deliver stem cell - derived islet replacement therapies to patients with type 1 diabetes as well as patients with type 2 disease that require insulin.
The Company's pluripotent stem cell - derived islet cell replacement therapy, the PEC - Direct ™ product candidate, has the potential to be a breakthrough treatment for high - risk type 1 diabetes.
A number of treatments exist, including enzyme replacement therapy and hematopoietic stem cell transplantation, but efficacy depends upon diagnosing the disease and its specific form as early as possible.
The VC - 01 product candidate is the first embryonic stem cell - derived islet replacement therapy to reach clinical testing and is currently being evaluated in patients with T1D who have minimal to no insulin - producing beta cell function.
SAN DIEGO, June 22, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced two presentations at ISSCR 2016 Annual Meeting.
«In particular, Dr. Rezania, who joined us as part of the BetaLogics asset consolidation, is reporting on advances that further bolster our leadership position in the field of stem cell - derived cell replacement therapy.
The author's goal with this insider's guide is to give readers the information needed to distinguish between the... View Details Stem Cell Revolution: Discover 26 Disruptive Technological Advances to Stem Cell Activation by Joseph Christiano (Author) Addressing chronic back pain, diabetes, joint replacements, osteoarthritis, neurological issues, and more, Joseph «Dr. Joe» Christiano reveals how this cutting - edge therapy can rapidly replace damaged cells in the body with no side effects or allergic reactions.
Stem cell therapy offers the possibility of using these stem cells to grow into replacements for injured or diseased tissues such as bone, cartilage, muscle, nerves, and soStem cell therapy offers the possibility of using these stem cells to grow into replacements for injured or diseased tissues such as bone, cartilage, muscle, nerves, and sostem cells to grow into replacements for injured or diseased tissues such as bone, cartilage, muscle, nerves, and so on.
Dr. Walls particularly enjoys the challenges of advanced orthopedics, including total joint replacement (hip and elbow), angular limb deformities, small joint arthroscopy, performance animal / sports medicine, and stem cell therapies.
Our surgeons utilize the latest techniques including stem cell therapy, Tibial Plateau Leveling Osteotomy (TPLO), Trochleoplasty for luxating patellas, PennHIPevaluations, pubic symphysiodesis in puppies, Triple Pelvic Osteotomy (TPO), total hip replacement, Femoral Head Osteotomy (FHO), arthroscopy, reconstructive surgery, and limb salvage operations.
About Blog Heal naturally by regenerative stem cell therapy instead of knee replacement treatment.